The Fort Worth Press - The winding, fitful path to weight loss drug Ozempic

USD -
AED 3.672504
AFN 64.500413
ALL 81.998222
AMD 357.803769
ANG 1.790403
AOA 917.999811
ARS 1559.268201
AUD 1.490235
AWG 1.8025
AZN 1.677673
BAM 1.782854
BBD 2.012735
BDT 124.411466
BGN 1.77347
BHD 0.377107
BIF 3003.463993
BMD 1
BND 1.288879
BOB 11.707704
BRL 5.8789
BSD 0.999385
BTN 93.383593
BWP 14.117915
BYN 2.997958
BYR 19600
BZD 2.009818
CAD 1.431185
CDF 2284.999488
CHF 0.84219
CLF 0.025569
CLP 1006.340199
CNY 6.667798
CNH 6.66638
COP 3354.69
CRC 444.296568
CUC 1
CUP 23.984575
CVE 100.51779
CZK 22.209901
DJF 177.949763
DKK 6.798375
DOP 60.418499
DZD 137.054003
EGP 53.737198
ERN 15
ETB 164.020438
EUR 0.90945
FJD 2.286305
FKP 0.76038
GBP 0.759955
GEL 2.590077
GGP 0.76038
GHS 11.732317
GIP 0.76038
GMD 73.498737
GNF 8859.697901
GTQ 7.637401
GYD 209.002981
HKD 7.845035
HNL 26.862474
HRK 6.831965
HTG 131.020966
HUF 335.089756
IDR 18264.85
ILS 3.265055
IMP 0.76038
INR 93.269599
IQD 1514.984389
IRR 1933164.499323
ISK 124.600364
JEP 0.76038
JMD 158.502846
JOD 0.709008
JPY 159.831499
KES 130.050035
KGS 87.449403
KHR 4071.103008
KMF 449.000081
KPW 900.00035
KRW 1329.059689
KWD 0.31167
KYD 0.832836
KZT 444.440393
LAK 22515.053033
LBP 89590.84067
LKR 332.58429
LRD 167.887437
LSL 17.179374
LTL 2.95274
LVL 0.60489
LYD 6.463111
MAD 9.953508
MDL 18.347645
MGA 4544.315048
MKD 55.995815
MMK 2099.801407
MNT 3600.814049
MOP 8.076574
MRU 40.612196
MUR 46.840183
MVR 15.39267
MWK 1732.793079
MXN 18.846835
MYR 4.110597
MZN 63.902977
NAD 17.179061
NGN 1350.2502
NIO 36.77352
NOK 9.68358
NPR 149.412703
NZD 1.81177
OMR 0.384498
PAB 0.999385
PEN 3.411744
PGK 4.495877
PHP 63.661967
PKR 276.292258
PLN 4.01253
PYG 6255.270079
QAR 3.643308
RON 4.863402
RSD 106.986978
RUB 82.003338
RWF 1478.922348
SAR 3.751382
SBD 8.137041
SCR 14.002012
SDG 601.496186
SEK 10.14248
SGD 1.289135
SHP 0.757117
SLE 22.799161
SLL 20969.503664
SOS 571.095199
SRD 37.3845
STD 20697.981008
STN 22.333535
SVC 8.744046
SYP 13002.000337
SZL 17.176326
THB 33.85698
TJS 9.188906
TMT 3.5
TND 3.026701
TOP 2.40776
TRY 50.467602
TTD 6.7815
TWD 32.947897
TZS 2659.998026
UAH 45.116247
UGX 4186.987794
UYU 40.602566
UZS 12002.151381
VES 916.62795
VND 25748
VUV 120.949122
WST 2.823281
XAF 596.560073
XAG 0.022103
XAU 0.000267344295
XCD 2.70255
XCG 1.801044
XDR 0.707052
XOF 596.560073
XPF 108.71765
YER 236.550191
ZAR 17.24949
ZMK 9001.21272
ZMW 20.525699
ZWL 321.999592
SSP 5879.599296
MXV 2.11322
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

The winding, fitful path to weight loss drug Ozempic
The winding, fitful path to weight loss drug Ozempic / Photo: © The Rockefeller University/AFP

The winding, fitful path to weight loss drug Ozempic

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so what was that journey like for the scientists involved?

Text size:

Joel Habener of Massachusetts General Hospital and Svetlana Mojsov of The Rockefeller University, who are being honored with the prestigious Lasker Award for their role in the research, spoke to AFP about how they made the discoveries that changed the way we think about weight.

The pair will share the award -- often considered a predictor of future Nobel success -- as well as an honorarium of $250,000 with Lotte Bjerre Knudsen of Novo Nordisk, which manufactures Ozempic.

- Early molecular biology -

Obesity has escalated into a global health crisis, affecting 900 million people worldwide -- including over 40 percent of Americans and nearly a quarter of Europeans.

But back in the mid-1970s, when Habener, now 87, began his career as a physician-scientist, his curiosity was focused on diabetes.

He was particularly interested in the pancreatic hormone glucagon, known for raising blood sugar levels -- the opposite effect of insulin, which was already used as a treatment for diabetes.

By understanding and potentially modulating glucagon's effects, Habener believed he could uncover new ways to manage diabetes.

To pursue this, he turned to the emerging field of molecular biology, aiming to isolate and clone the gene that encodes glucagon.

- Fortuitous turn to fish -

But he quickly hit a roadblock: the US National Institutes of Health had just banned the type of research he planned to conduct on mammalian genes.

This pushed him to pivot to studying the anglerfish, a creature with a unique endocrine organ outside the pancreas.

"It turned out to be a godsend in terms of simplicity," he recalled, describing the eureka moment when he isolated a precursor protein that gave rise to glucagon -- as well as a second hormone that resembled glucagon.

Though Habener didn't realize its significance at the time, this turned out to be the fish-equivalent of "GLP-1," the foundation for today's diabetes and obesity drugs.

"That's what's beautiful about discovery research," he said. "By exploring the unknown, you get surprises."

- Identifying GLP-1's potential -

Mojsov, who emigrated from Yugoslavia, took the early discoveries made by Habener and others further with several important contributions.

Poring over the hormone's structure, she correctly predicted the active form of GLP-1 and devised innovative chemistry methods to synthesize it.

She also proposed that GLP-1 would be released in the intestines and act to trigger insulin production. Together with Habener and others, she proved this theory through lab experiments and human trials, identifying its therapeutic potential.

"I was sure it would be a good drug for diabetes," said the 76-year-old. However, at the time, there was no scientific evidence that hormones could regulate weight.

It was only later studies by Habener, Mojsov, and others that revealed GLP-1's ability to slow stomach emptying and its interaction with receptors in the brain, helping to curb appetite and possibly even address substance addictions.

- New era of treatments -

Starting in the 1990s, Knudsen, the head of GLP-1 therapeutics at Novo Nordisk, and her team built on these breakthroughs to develop treatments for diabetes (Ozempic) and obesity (Wegovy), extending the drug's therapeutic effects from just a few hours to over a week.

"Now we can see that GLP-1 actually has a much broader spectrum of health benefits," said Mojsov, though she laughs off the "miracle drug" label.

Obese patients "lose a lot of weight but also their muscle mass, and that's also very serious," she stressed. "I think it should never be taken for cosmetic reasons."

GLP-1 drugs have now been approved for treating cardiovascular disease, and emerging evidence suggests they may offer protective effects against dementia.

Though the exact mechanism remains unclear, Habener suggests their ability to suppress inflammatory pathways might be the common link.

As for the future, Mojsov is optimistic. She foresees a new generation of similar drugs that will further minimize side effects and target an even broader range of diseases.

D.Ford--TFWP